302803-72-1

Usage

Uses

Used in Anticancer Applications:
HPI-4, Hedgehog Pathway Inhibitor 4, is used as an anticancer agent for targeting the Hedgehog signaling pathway, which is often dysregulated in various types of cancer. By inhibiting this pathway, HPI-4 can potentially suppress tumor growth and progression.
Used in Drug Delivery Systems:
In the pharmaceutical industry, HPI-4, Hedgehog Pathway Inhibitor 4, is used as a component in drug delivery systems to enhance the efficacy and bioavailability of anticancer drugs. Its ability to target the Hedgehog signaling pathway makes it a promising candidate for the development of novel therapeutic strategies against cancer.
Used in Ciliogenesis Inhibition:
HPI-4, Hedgehog Pathway Inhibitor 4, is used as a ciliogenesis inhibitor for disrupting primary cilia formation, which is essential for the proper functioning of cells. This application can be relevant in various research and therapeutic contexts, particularly in understanding the role of cilia in cellular processes and diseases.
Used in Inhibition of Dynein ATPase in Leishmania:
In the field of parasitology, HPI-4, Hedgehog Pathway Inhibitor 4, is used for the inhibition of dynein ATPase in Leishmania, a protozoan parasite responsible for the disease leishmaniasis. By targeting this enzyme, HPI-4 can potentially help in the development of new treatments for leishmaniasis.
Used in Inhibition of mTORC1 Activity:
HPI-4, Hedgehog Pathway Inhibitor 4, is used as an inhibitor of mammalian target of rapamycin complex 1 (mTORC1) activity in both uninfected and human cytomegalovirus (HCMV)-infected cells. This application can be relevant in the development of antiviral therapies and understanding the role of mTORC1 in cellular activation and disease progression.

Biochem/physiol Actions

HPI-4 is a Hedgehog pathway inhibitor; ciliogenesis inhibitor. The Hedgehog (HH) signaling pathway is targeted for anti-cancer therapeutics. A key signaling molecule in HH pathway, Smoothened (Smo), has been the target of pharmacological intervention, which has resulted in multiple Smo antagonists including Cyclopamine. However, the oncogenic form of Smo is resistant to Cyclopamine, so the identification of inhibitors of downstream effectors, such as the transcription factors Gli1 and Gli2, is important. Four small molecules were identified to inhibit HH downstream of Smo, HPI-1, HPI-2, HPI-3, and HPI-4. HPI-4 blocked HH pathway activation by SAG, decreased Smo ciliary accumulation, decreased HH activity in a consitutively active HH cell line, and decreased Gli1 and Gli2, processing, and stability. HPI-4 inhibited proliferation of cerebellar granula neuron precursor cells, an important model of HH signaling. Cilia in HPI-4-treated cells were either truncated or absent. The mechanism of action of HPI-4 is hypothesized to be directly through perturbation of ciliogenesis, leading to disruption of Gli1/Gli2 activity, which is distinctly different from that of Cyclopamine.